William Blair analyst Ryan Daniels has maintained their bullish stance on OPRX stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ryan Daniels has given his Buy rating due to a combination of factors that highlight OptimizeRx’s strong financial performance and promising future outlook. The company reported impressive third-quarter results for 2025, with revenue and adjusted EBITDA surpassing expectations significantly. This robust performance is attributed to the continued strong digital marketing spend by pharmaceutical clients, who are increasingly investing in high-ROI digital solutions despite broader economic uncertainties.
Moreover, the management’s decision to raise both revenue and EBITDA guidance for the future, along with favorable RFP trends, suggests that the company’s growth trajectory is likely to persist into 2026. The company’s ability to embed more recurring-revenue and data services with its core customers is expected to enhance margins and improve revenue predictability. These positive developments provide a solid foundation for the company’s continued success, justifying the Buy rating.
In another report released yesterday, Lake Street also maintained a Buy rating on the stock with a $20.00 price target.